These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35794497)

  • 41. In Silico Screening of Potential Spike Glycoprotein Inhibitors of SARS-CoV-2 with Drug Repurposing Strategy.
    Wei TZ; Wang H; Wu XQ; Lu Y; Guan SH; Dong FQ; Dong CL; Zhu GL; Bao YZ; Zhang J; Wang GY; Li HY
    Chin J Integr Med; 2020 Sep; 26(9):663-669. PubMed ID: 32740825
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
    David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
    Molecules; 2021 May; 26(11):. PubMed ID: 34072087
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods.
    Unni S; Aouti S; Thiyagarajan S; Padmanabhan B
    J Biosci; 2020; 45(1):. PubMed ID: 33184246
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Computational prediction of the effect of mutations in the receptor-binding domain on the interaction between SARS-CoV-2 and human ACE2.
    Celik I; Khan A; Dwivany FM; Fatimawali ; Wei DQ; Tallei TE
    Mol Divers; 2022 Dec; 26(6):3309-3324. PubMed ID: 35138508
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Venetoclax Decreases the Expression of the Spike Protein through Amino Acids Q493 and S494 in SARS-CoV-2.
    Chen CC; Zhuang ZJ; Wu CW; Tan YL; Huang CH; Hsu CY; Tsai EM; Hsieh TH
    Cells; 2022 Jun; 11(12):. PubMed ID: 35741053
    [TBL] [Abstract][Full Text] [Related]  

  • 46.
    Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
    OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of a novel peptide to prevent entry of SARS-CoV-2 into lung and olfactory bulb cells of hACE2 expressing mice.
    Su P; Zhai D; Wong AHC; Liu F
    Mol Brain; 2022 Aug; 15(1):71. PubMed ID: 35945596
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An
    Stalin A; Lin D; Senthamarai Kannan B; Feng Y; Wang Y; Zhao W; Ignacimuthu S; Wei DQ; Chen Y
    J Biomol Struct Dyn; 2022 Oct; 40(16):7408-7423. PubMed ID: 33685364
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structure-Based Development of SARS-CoV-2 Spike Interactors.
    Squeglia F; Romano M; Esposito L; Barra G; Campiglia P; Sala M; Scala MC; Ruggiero A; Berisio R
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628409
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aptamer Blocking Strategy Inhibits SARS-CoV-2 Virus Infection.
    Sun M; Liu S; Wei X; Wan S; Huang M; Song T; Lu Y; Weng X; Lin Z; Chen H; Song Y; Yang C
    Angew Chem Int Ed Engl; 2021 Apr; 60(18):10266-10272. PubMed ID: 33561300
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Regulation of Angiotensin-Converting Enzyme 2: A Potential Target to Prevent COVID-19?
    Hu Y; Liu L; Lu X
    Front Endocrinol (Lausanne); 2021; 12():725967. PubMed ID: 34745001
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Investigation of the genetic variation in ACE2 on the structural recognition by the novel coronavirus (SARS-CoV-2).
    Guo X; Chen Z; Xia Y; Lin W; Li H
    J Transl Med; 2020 Aug; 18(1):321. PubMed ID: 32831104
    [TBL] [Abstract][Full Text] [Related]  

  • 53. "Molecular Masks" for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry.
    Shukla SP; Cho KB; Rustagi V; Gao X; Fu X; Zhang SX; Guo B; Udugamasooriya DG
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445669
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2.
    Lee RK; Li TN; Chang SY; Chao TL; Kuo CH; Pan MY; Chiou YT; Liao KJ; Yang Y; Wu YH; Huang CH; Juan HF; Hsieh HP; Wang LH
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409412
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell-entry process, and cytokine storm in COVID-19.
    Kar P; Saleh-E-In MM; Jaishee N; Anandraj A; Kormuth E; Vellingiri B; Angione C; Rahman PKSM; Pillay S; Sen A; Naidoo D; Roy A; Choi YE
    J Cell Biochem; 2022 May; 123(5):964-986. PubMed ID: 35342986
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Coevolution, Dynamics and Allostery Conspire in Shaping Cooperative Binding and Signal Transmission of the SARS-CoV-2 Spike Protein with Human Angiotensin-Converting Enzyme 2.
    Verkhivker G
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158276
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In silico Nigellidine (N. sativa) bind to viral spike/active-sites of ACE1/2, AT1/2 to prevent COVID-19 induced vaso-tumult/vascular-damage/comorbidity.
    Maiti S; Banerjee A; Kanwar M
    Vascul Pharmacol; 2021 Jun; 138():106856. PubMed ID: 33746069
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In silico study of some selective phytochemicals against a hypothetical SARS-CoV-2 spike RBD using molecular docking tools.
    Nag A; Paul S; Banerjee R; Kundu R
    Comput Biol Med; 2021 Oct; 137():104818. PubMed ID: 34481181
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent.
    Basit A; Ali T; Rehman SU
    J Biomol Struct Dyn; 2021 Jul; 39(10):3605-3614. PubMed ID: 32396773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.